Analysis of COVID-19's effects and long-term health impacts
National Pandemic Cohort Network - High-resolution Platform (HAP) Analysis of the Pathophysiology and Pathology of Coronavirus Disease 2019 (COVID-19), Including Chronic Morbidity
This study is trying to understand the long-term health effects of COVID-19 by collecting data from patients who were hospitalized in Germany and following them for three years after their symptoms started.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 750 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Charite University, Berlin, Germany Academic / other |
| Locations | 11 sites (Freiburg, Baden-Württemberg and 10 other locations) |
| Trial ID | NCT04747366 on ClinicalTrials.gov |
What this trial studies
The NAPKON-HAP platform is designed to collect extensive data and biosamples from patients hospitalized with COVID-19 in Germany. This observational study gathers information three times a week during hospitalization and at follow-up visits over three years post-symptom onset. It aims to document various clinical parameters, including organ involvement, quality of care, and long-term morbidity, to support research on COVID-19 and future pandemics.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who are hospitalized with a confirmed SARS-CoV-2 infection.
Not a fit: Patients who refuse to participate or have conditions preventing additional blood sampling may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of COVID-19's long-term effects and inform better treatment strategies.
How similar studies have performed: Other studies have successfully utilized similar observational approaches to understand the long-term impacts of infectious diseases.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Willingness to participate in the study (consent to participate by patient or appropriate legal representative) or inclusion via deferred consent * Hospitalization at time of enrollment * Positive evidence for SARS-CoV-2 infection with PCR (polymerase chain reaction) or initial positive rapid diagnostic test in conjunction with typical clinical symptoms, confirmed by a later positive PCR test. Exclusion Criteria: * Refusal to participate by patient, or appropriate legal representative * Any condition that prohibits supplemental blood-sampling beyond routine blood drawing
Where this trial is running
Freiburg, Baden-Württemberg and 10 other locations
- University Medical Center Freiburg Department of Internal Medicine II Department of Infectiology — Freiburg, Baden-Württemberg, Germany (Recruiting)
- University Hospital Heidelberg Clinic for Gastroenterology, Infections, Poisoning — Heidelberg, Baden-Württemberg, Germany (Recruiting)
- Clinic of the University of Munich Medical Clinic and Polyclinic III — Munich, Bayern, Germany (Recruiting)
- University Hospital Frankfurt Medical Clinic II Department of infectiology — Frankfurt, Hessen, Germany (Recruiting)
- University Hospital Giessen (+Marburg) Medical Clinic II Pneumology and internal intensive care medicine Infectiology, Gastroenterology, Nephrology — Gießen, Hessen, Germany (Recruiting)
- Hanover Medical School Clinic for Pneumology — Hannover, Niedersachsen, Germany (Recruiting)
- University Hospital Cologne Internal Medicine I and Hematology and Oncology, Infectiology, additional qualification in Emergency Medicine — Cologne, Nordrhein-Westfalen, Germany (Recruiting)
- University Medical Center Schleswig-Holstein (Campus Kiel): Internal medicine, gastroenterology, pneumology, allergology, sleep medicine, emergency medicine, intensive care — Kiel, Schleswig-Holstein, Germany (Recruiting)
- University Medical Center Schleswig-Holstein (Campus Lübeck): Internal medicine, gastroenterology, pneumology, allergology, sleep medicine, emergency medicine, intensive care — Lübeck, Schleswig-Holstein, Germany (Recruiting)
- University Hospital Jena Department of Internal Medicine IV — Jena, Thüringen, Germany (Recruiting)
- Charité University Hospital Berlin Medical Clinic Infectiology and Pneumology CCM/CVK — Berlin, Germany (Recruiting)
Study contacts
- Principal investigator: Martin Witzenrath, Prof. Dr. med. — Charite University Hospital Berlin
- Study coordinator: Martin Witzenrath, Prof. Dr. med.
- Email: martin.witzenrath@charite.de
- Phone: +49 30 450 553 892
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.